Department of Translational and Applied Genomics, Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA; email:
Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA; email:
Annu Rev Genomics Hum Genet. 2022 Aug 31;23:173-192. doi: 10.1146/annurev-genom-111021-032401. Epub 2022 Apr 1.
Actionability is an important concept in medicine that does not have a well-accepted standard definition, nor is there a general consensus on how to establish it. Medical actionability is often conflated with clinical utility, a related but distinct concept. This lack of clarity contributes to practice variation and inconsistent coverage decisions in genomic medicine, leading to the potential for systematic bias in the use of evidence-based interventions. We clarify how medical actionability and clinical utility are distinct and then discuss the spectrum of actionability, including benefits for the person, the family, and society. We also describe applications across the life course, including prediction, diagnosis, and treatment. Current challenges in assessing the medical actionability of identified genomic variants include gaps in the evidence, limited contexts with practice guidelines, and subjective aspects of medical actionability. A standardized and authoritative assessment of medical actionability is critical to implementing genomic medicine in a fashion that improves population health outcomes and reduces health disparities.
可操作性是医学中的一个重要概念,但它没有一个被广泛接受的标准定义,也没有关于如何确定它的普遍共识。医学可操作性常常与临床实用性混淆,后者是一个相关但不同的概念。这种不明确性导致了基因组医学实践中的差异和不一致的覆盖决策,从而有可能导致基于证据的干预措施的使用存在系统性偏差。我们澄清了医学可操作性和临床实用性的区别,然后讨论了可操作性的范围,包括对个人、家庭和社会的益处。我们还描述了贯穿整个生命周期的应用,包括预测、诊断和治疗。目前,在评估已确定的基因组变异的医学可操作性方面存在一些挑战,包括证据不足、实践指南的有限背景以及医学可操作性的主观性。对医学可操作性进行标准化和权威性评估对于以改善人口健康结果和减少健康差距的方式实施基因组医学至关重要。